FGF2 and invasive carcinoma: TIMER2.0 was used to identify the correlation between EGFR and other gene expressions in breast-invasive carcinoma subtypes with purity adjustments such as FGF2, FGFBP1, TGFA, TGFBR3, and IGF1R in all BRCA patients.